Prevalence of cerebral and pulmonary thrombosis in patients with cyanotic congenital heart disease. Issue 19 (5th June 2015)

• Record Type: Journal Article
• Authors: Jensen, A S; Idorn, L; Thomsen, C; von der Recke, P; Mortensen, J; Sørensen, K E; Thilén, U; Nagy, E; Kofoed, K F; Ostrowski, S R; Søndergaard, L
• Is Part Of: Heart. Volume 101:Issue 19(2015)
• Page Start: 1540
• Page End: 1546
• Publication Date: 2015-06-05
• Subjects: Heart -- Diseases -- Treatment -- Periodicals; Cardiology -- Periodicals; 616.12
• DOI: 10.1136/heartjnl-2015-307657
• Languages: English
• ISSNs: 1355-6037

Abstract

Abstract : Background: Patients with cyanotic congenital heart disease (CCHD) have a high prevalence of thrombosis, the most frequently described locations being the cerebral and pulmonary vessels. The reported prevalence of both cerebral infarction and pulmonary thrombosis has been highly variable. The aim of this study was to examine the prevalence of both cerebral and pulmonary thrombosis in CCHD according to medical history and imaging. In addition, the role of known erythrocytosis and haemostatic abnormalities as risk factors was evaluated. Methods and results: A cross-sectional descriptive study examining 98 stable adult patients with CCHD with a medical questionnaire, blood samples, MRI of the cerebrum (n=72), multidetector CT imaging (MDCT) of the thorax (n=76) and pulmonary scintigraphy (ventilation/perfusion/single-photon emission computerised tomography/CT) (n=66). The prevalence of cerebral infarction and pulmonary thrombosis according to imaging were 47% and 31%, respectively. Comparing the findings with previous medical history revealed a large under-reporting of thrombosis with only 22% of the patients having a clinical history of stroke and 25% of pulmonary thrombosis. There was no association between the degree of erythrocytosis or haemostatic abnormalities and the prevalence of thrombosis. Conclusions: Patients with CCHD have a prevalence of both cerebral and pulmonary thrombosis of around 30%–40%, which is much higher than that reported previously. Furthermore, there is a large discrepancy between clinical history and imaging findings, suggesting a high prevalence of silent thrombotic events. Neither erythrocytosis nor haemostatic abnormalities were associated with the prevalence of thrombosis in patients with CCHD. Trial registration number: http://www.cvk.sum.dk/CVK/Home/English.aspx (H-KF-2006-4068).